Editorial

References

• Suhadolnik RJ, Reichenbach NL, Hitzges P et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18 Suppl 1:S96–104.
   PubMedGoogle Scholar
• Suhadolnik RJ, Reichenbach NL, Hitzges P et al. Changes in the 2-5A synthe-tase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. In Vivo 1994; 8:599–604.
   PubMedGoogle Scholar
• Suhadolnik RJ, Reichenbach NL, Hitzges PM et al. RNA drug therapy acting via the 2-5A synthetase/RNase L pathway. Ann N Y Acad Sci 1993; 685:756–757.
   PubMed Web of Science ®Google Scholar
• Demettre E, Bastide L, D'Haese A et al. Ribonuclease L proteolysis in periph-eral blood mononuclear cells of chronic fatigue syndrome patients. J Biol Chem 2002; 277:35746–35751.
   Google Scholar
• Suhadolnik RJ, Peterson DL, O'Brien K et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Inter-feron Cytokine Res 1997; 17:377–385.
   Google Scholar
• Vojdani A, Choppa PC, Lapp CW. Downregulation of RNase L inhibitor corre-lates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome. J Clin Lab Immunol 1998; 50:1–16.
   Google Scholar
• Vojdani A, Lapp CW. Interferon-induced proteins are elevated in blood sam-ples of patients with chemically or virally induced chronic fatigue syndrome. Immuno-pharmacol Immunotoxicol 1999; 21:175–202.
   PubMed Web of Science ®Google Scholar
• De Meirleir K, Bisbal C, Campine I et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 2000; 108:99–105.
   PubMed Web of Science ®Google Scholar
• Shetzline SE, Martinand-Mari C, Reichenbach NL et al. Structural and func-tional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res 2002; 22:443–456.
   PubMed Web of Science ®Google Scholar
• Vojdani A, Lapp CW. Interferon-induced proteins are elevated in blood sam-ples of patients with chemically or virally induced chronic fatigue syndrome. Immuno-pharmacol Immunotoxicol 1999; 21:175–202.
   PubMed Web of Science ®Google Scholar
• Gow JW, Simpson K, Behan PO et al. Antiviral pathway activation in patients with chronic fatigue syndrome and acute infection. Clin Infect Dis 2001; 33:2080–2081.
   PubMed Web of Science ®Google Scholar
• Huppertz HI, Becker K, Kreth HW. Clinical value of measuring the inter-feron-induced enzyme 2'-5'-oligoadenylate synthetase in children. Acta Paediatr 1992; 81:329–334.
   Google Scholar
• Brewster FE, Byron KS, Sullivan IL. Immunoregulation during acute infection with Epstein-Barr virus: dynamics of interferon and 2',5'-oligoadenylate synthetase activity. J Infect Dis 1985; 151:1109–1115.
   Google Scholar
• Heathcote J, Kim YI, Yim CK et al. Interferon-associated lymphocyte 2',5 oligoadenylate synthetase in acute and chronic viral hepatitis. Hepatology 1989; 9:105–109.
   PubMed Web of Science ®Google Scholar
• Okuno T, Shindo M, Arai K et al. Detection of 2',5' oligoadenylate synthetase activity in acute viral hepatitis with special reference to histologic features in the acute stage. Gastroenterol Jpn 1991; 26:162–169.
   PubMedGoogle Scholar
• Schattner A, Wallach D, Merlin Get al. Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases. Lancet 1981; 2:497–500.
   Google Scholar
• Vonderheid EC, Suhadolnik RJ, Sobel EL et al. Increased 2',5'-oligoadenylate synthetase activity in blood mononuclear leukocytes from patients with advanced cuta-neous T- cell lymphoma. ClM Immunol Immunopathol 1984; 31:138–150.
   PubMedGoogle Scholar
• Choppa PC, Vojdani A, Tagle C et al. Multiplex PCR for the detection of Myco-plasma fermentans, M. hominis and M. penetrans in cell cultures and blood samples of patients with chronic fatigue syndrome. Mol Cell Probes 1998; 12:301–308.
   Google Scholar
• Nasralla M, Haier J, Nicolson GL. Multiple mycoplasmal infections detected in blood of patients with chronic fatigue syndrome and/or fibromyalgia syndrome. Eur J ClM Microbiol Infect Dis 1999; 18:859–865.
   Google Scholar
• Vojdani A, Choppa PC, Tagle C et al. Detection of Mycoplasma genus and Mycoplasma fermentans by PCR in patients with Chronic Fatigue Syndrome. FEMS Immunol Med Microbiol 1998; 22:355–365.
   PubMed Web of Science ®Google Scholar
• Komaroff AL, Bell DS, Cheney PR, Lo SC. Absence of antibody to Myco-plasma fermentans in patients with chronic fatigue syndrome. ClM Infect Dis 1993; 17:1074–1075.
   PubMed Web of Science ®Google Scholar
• Nijs J, Nicolson GL, De Becker Pet al. High prevalence of Mycoplasma infec-tions among European chronic fatigue syndrome patients. Examination of four Myco-plasma species in blood of chronic fatigue syndrome patients. FEMS Immunol Med Microbiol 2002; 34:209–214.
   Google Scholar
• Buffet-Janvresse C, Magard H, Robert N, Hovanessian AG. Assay and the lev-els of 2-5A-synthetase in lymphocytes of patients with viral, bacterial and autoimmune diseases. Ann Immunol (Paris) 1983; 134D:247–258.
   Google Scholar
• Buffet-Janvresse C, Hovanessian AG. Enzyme markers for the presence of cir-culating interferon: 2-5A synthetase in blood lymphocytes and protein kinase in platelet-rich plasma. Proc Soc Exp Biol Med 1984; 175:169–175.
   Google Scholar
• Chousterman S, Chousterman M, Reinert P, Thang MN. Clinical value of the determination of an interferon-induced enzyme activity: studies of the 2'5' oligo-adenylate synthetase activity in peripheral blood lymphocytes of patients. Biomed Pharmacother 1983; 37:176–180.
   PubMed Web of Science ®Google Scholar
• Pereyra BS, Falcoff R, Falcoff E, Lemonnier D. Interferon induction by Lactobacillus bulgaricus and Streptococcus the rmophilus in mice. Eur Cytokine Netw 1991; 2:299–303.
   PubMedGoogle Scholar
• Sasaki K, Fujita I, Hamasaki Y, Miyazaki S. Differentiating between bacterial and viral infection by measuring both C-reactive protein and 2'-5'-oligoadenylate synthetase as inflammatory markers. J Infect Chemother 2002; 8:76–80.
   PubMedGoogle Scholar
• Schattner A, Wallach D, Merlin G et al. Variation of (2'-5') oligo A synthetase level in lymphocytes and granulocytes of patients with viral infections and leukemia. J Inteiferon Res 1982; 2:355–361.
   PubMedGoogle Scholar
• Schattner A, Merlin G, Bregman V et al. (2'-5') Oligo A synthetase in human polymorphonuclear cells increased activity in interferon treatment and in viral infec-tions. Clin Exp Immunol 1984; 57:265–270.
   PubMed Web of Science ®Google Scholar
• Holmes GP, Kaplan JE, Gantz NM et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108:387–389.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Straus SE, Hickie I et al. The chronic fatigue syndrome: a compre-hensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121:953–959.
   PubMed Web of Science ®Google Scholar